Biotech | October 15, 2021
Exelixis in-licenses second anti-cancer compound from Aurigene
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
Through this initiative, the Centre for Trauma will create curriculums and facilitate trauma-related courses for healthcare professionals at both urban and grassroot levels
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
It recommends using the vaccine to prevent the spread of the disease
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
Subscribe To Our Newsletter & Stay Updated
